Birdwatch Archive

Birdwatch Note

2024-03-20 03:12:22 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

福島氏らの内容は論文検索サイトでエビデンス能力が低い症例報告↓ https://co-medical.mynavi.jp/contents/therapistplus/kokushi/drill/5074/ を含めた論文の検索結果の計数です。 http://cont.o.oo7.jp/51_3/w43.pdf 適切な対照条件と比較しての発症率の調査やそのメタ解析ではなくこれらの症例がワクチンの副反応であるわけではない事に注意が必要です。 また氏があげた多数の研究有との疾患(↓表3)は http://cont.o.oo7.jp/51_3/w43.pdf 頭痛、心筋炎、リンパ節腫大、アナフィラキシーのように当局より以前より周知されているリスク、副反応であったり↓ https://www.cov19-vaccine.mhlw.go.jp/qa/0002.html ギランバレーや血栓症はベクターワクチンでのみメタ解析で未接種より高リスクだった↓事に注意が必要です https://link.springer.com/article/10.1007/s00415-024-12186-7 (下記3.4.2) https://www.mdpi.com/2076-393X/10/4/596

Written by F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1770242520846647796

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1770287237240177037
  • noteId - 1770287237240177037
  • participantId -
  • noteAuthorParticipantId - F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D Participant Details
  • createdAtMillis - 1710904342361
  • tweetId - 1770242520846647796
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 1
  • misleadingManipulatedMedia - 1
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 1
  • misleadingUnverifiedClaimAsFact - 1
  • misleadingSatire - 0
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • 福島氏らの内容は論文検索サイトでエビデンス能力が低い症例報告↓ https://co-medical.mynavi.jp/contents/therapistplus/kokushi/drill/5074/ を含めた論文の検索結果の計数です。 http://cont.o.oo7.jp/51_3/w43.pdf 適切な対照条件と比較しての発症率の調査やそのメタ解析ではなくこれらの症例がワクチンの副反応であるわけではない事に注意が必要です。 また氏があげた多数の研究有との疾患(↓表3)は http://cont.o.oo7.jp/51_3/w43.pdf 頭痛、心筋炎、リンパ節腫大、アナフィラキシーのように当局より以前より周知されているリスク、副反応であったり↓ https://www.cov19-vaccine.mhlw.go.jp/qa/0002.html ギランバレーや血栓症はベクターワクチンでのみメタ解析で未接種より高リスクだった↓事に注意が必要です https://link.springer.com/article/10.1007/s00415-024-12186-7 (下記3.4.2) https://www.mdpi.com/2076-393X/10/4/596

Note Status History

createdAt timestampMillisOfFirstNonNMRStatus firstNonNMRStatus timestampMillisOfCurrentStatus currentStatus timestampMillisOfLatestNonNMRStatus mostRecentNonNMRStatus participantId
2024-03-20 03:12:22 UTC
(1710904342361)
2024-03-20 07:59:06 UTC
(1710921546160)
CURRENTLY_RATED_HELPFUL 2024-03-21 01:30:52 UTC
(1710984652589)
CURRENTLY_RATED_HELPFUL 2024-03-20 07:59:06 UTC
(1710921546160)
CURRENTLY_RATED_HELPFUL

Note Ratings

rated at rated by
2024-03-20 18:12:49 -0500 Rating Details
2024-03-20 17:40:11 -0500 Rating Details
2024-03-20 09:30:44 -0500 Rating Details
2024-03-20 09:12:27 -0500 Rating Details
2024-03-20 08:33:40 -0500 Rating Details
2024-03-20 06:44:21 -0500 Rating Details
2024-03-20 06:25:04 -0500 Rating Details
2024-03-20 05:29:00 -0500 Rating Details
2024-03-20 03:02:42 -0500 Rating Details
2024-03-20 00:41:35 -0500 Rating Details
2024-03-20 00:26:05 -0500 Rating Details
2024-03-20 00:21:16 -0500 Rating Details
2024-03-19 23:18:59 -0500 Rating Details
2024-03-19 23:18:15 -0500 Rating Details
2024-03-19 23:18:15 -0500 Rating Details
2024-03-19 23:17:36 -0500 Rating Details
2024-03-19 23:14:53 -0500 Rating Details
2024-03-19 23:00:24 -0500 Rating Details
2024-03-19 22:57:43 -0500 Rating Details
2024-03-19 22:53:54 -0500 Rating Details
2024-03-19 22:51:07 -0500 Rating Details
2024-03-19 22:45:33 -0500 Rating Details
2024-03-19 22:45:09 -0500 Rating Details
2024-03-19 22:41:37 -0500 Rating Details
2024-03-19 22:40:08 -0500 Rating Details
2024-03-19 22:39:23 -0500 Rating Details
2024-03-19 22:39:08 -0500 Rating Details
2024-03-19 22:34:04 -0500 Rating Details
2024-03-19 22:32:30 -0500 Rating Details
2024-03-19 22:32:29 -0500 Rating Details
2024-03-19 22:31:56 -0500 Rating Details
2024-03-19 22:30:43 -0500 Rating Details
2024-03-19 22:28:47 -0500 Rating Details
2024-03-19 22:28:26 -0500 Rating Details
2024-03-19 22:19:34 -0500 Rating Details
2024-03-19 22:17:26 -0500 Rating Details
2024-03-19 22:16:49 -0500 Rating Details
2024-03-21 13:18:40 -0500 Rating Details
2024-03-22 03:48:05 -0500 Rating Details
2024-03-21 22:26:12 -0500 Rating Details
2024-03-21 12:57:35 -0500 Rating Details
2024-03-21 11:37:52 -0500 Rating Details
2024-03-20 22:03:51 -0500 Rating Details
2024-03-20 17:48:12 -0500 Rating Details
2024-03-20 10:34:16 -0500 Rating Details
2024-03-20 10:12:29 -0500 Rating Details
2024-03-20 09:12:03 -0500 Rating Details
2024-03-20 08:54:43 -0500 Rating Details
2024-03-20 06:30:20 -0500 Rating Details
2024-03-20 05:14:41 -0500 Rating Details
2024-03-20 04:11:35 -0500 Rating Details
2024-03-20 02:38:22 -0500 Rating Details
2024-03-20 01:12:06 -0500 Rating Details
2024-03-20 00:59:40 -0500 Rating Details
2024-03-20 00:59:13 -0500 Rating Details
2024-03-20 00:40:34 -0500 Rating Details
2024-03-20 00:19:12 -0500 Rating Details
2024-03-19 23:59:20 -0500 Rating Details
2024-03-19 23:05:32 -0500 Rating Details
2024-03-19 23:04:12 -0500 Rating Details
2024-03-19 23:03:02 -0500 Rating Details
2024-03-19 23:02:19 -0500 Rating Details
2024-03-19 22:54:36 -0500 Rating Details
2024-03-19 22:46:28 -0500 Rating Details
2024-03-19 22:45:45 -0500 Rating Details
2024-03-19 22:44:59 -0500 Rating Details
2024-03-19 22:44:41 -0500 Rating Details
2024-03-19 22:42:32 -0500 Rating Details
2024-03-19 22:41:46 -0500 Rating Details
2024-03-19 22:41:38 -0500 Rating Details
2024-03-19 22:38:58 -0500 Rating Details
2024-03-19 22:35:57 -0500 Rating Details
2024-03-19 22:35:01 -0500 Rating Details
2024-03-19 22:33:57 -0500 Rating Details
2024-03-19 22:31:48 -0500 Rating Details
2024-03-19 22:21:25 -0500 Rating Details
2024-03-19 22:18:53 -0500 Rating Details
2024-03-19 22:16:59 -0500 Rating Details
2024-03-21 02:43:55 -0500 Rating Details
2024-03-20 22:51:37 -0500 Rating Details
2024-03-20 10:02:36 -0500 Rating Details
2024-03-20 08:59:17 -0500 Rating Details
2024-03-20 04:30:03 -0500 Rating Details
2024-03-20 04:09:00 -0500 Rating Details
2024-03-20 02:50:25 -0500 Rating Details
2024-03-20 01:48:25 -0500 Rating Details
2024-03-20 01:06:36 -0500 Rating Details
2024-03-20 00:40:31 -0500 Rating Details
2024-03-19 23:21:54 -0500 Rating Details
2024-03-19 23:17:58 -0500 Rating Details
2024-03-19 23:11:36 -0500 Rating Details
2024-03-19 23:04:47 -0500 Rating Details
2024-03-19 23:02:57 -0500 Rating Details
2024-03-19 22:58:42 -0500 Rating Details
2024-03-19 22:56:05 -0500 Rating Details
2024-03-19 22:53:01 -0500 Rating Details
2024-03-19 22:47:19 -0500 Rating Details
2024-03-19 22:47:06 -0500 Rating Details
2024-03-19 22:46:12 -0500 Rating Details
2024-03-19 22:36:15 -0500 Rating Details
2024-03-25 08:56:37 -0500 Rating Details
2024-03-27 04:24:47 -0500 Rating Details
2024-10-14 19:50:30 -0500 Rating Details